Table 1.

Patient characteristics at baseline

Characteristics	Anlotinib
	Total (n = 26)	Hormone receptor positive (n = 16)	Hormone receptor negative (n = 10)
Age, median (range)	56 (30–75)	56 (30–75)	50 (32–64)
Age (years), n (%)
≥ 65	3 (11.54)	3 (18.75)	0
< 65	23 (88.46)	13 (81.25)	10 (100)
ECOG, n (%)
0	7 (26.92)	5 (31.25)	2 (20.00)
1	16 (61.54)	10 (62.50)	6 (60.00)
2	3 (11.54)	1 (6.25)	2 (20.00)
Hormone receptor, n (%)
Positive	16 (61.54)	16 (100)	0
Negative	10 (38.46)	0	10 (100)
Type of metastatic site, n (%)
Non-visceral	4 (15.38)	2 (12.50)	2 (20.00)
Visceral	22 (84.62)	14 (87.50)	8 (80.00)
Number of metastatic sites, n (%)
1	3 (11.54)	2 (12.50)	1 (10.00)
2	12 (46.15)	7 (43.75)	5 (50.00)
≥ 3	11 (42.31)	7 (43.75)	4 (40.00)
Metastatic site, n (%)
Lymph nodes	13 (50.00)	7 (43.75)	6 (60.00)
Liver	9 (34.62)	8 (50.00)	1 (10.00)
Lung	17 (65.38)	9 (56.25)	8 (80.00)
Pleural effusion	6 (23.08)	3 (18.75)	3 (30.00)
Chest wall	2 (7.69)	1 (6.25)	1 (10.00)
Pericardial effusion	2 (7.69)	0	2 (20.00)
Bone	15 (57.69)	12 (75.00)	3 (30.00)
Neoadjuvant, n (%)
Yes	3 (11.54)	1 (6.25)	2 (20.00)
No	23 (88.46)	15 (93.75)	8 (80.00)
Adjuvant chemotherapy, n (%)
Yes	23 (88.46)	15 (93.75)	10 (100)
No	3 (11.54)	1 (6.25)	0
Adjuvant endocrine therapy, n (%)
Yes	16 (61.54)	16 (100)	0
No	10 (38.46)	0	10 (100)
Previous lines of systematic treatment, n (%)
≤ 2	14 (53.85)	8 (50.00)	6 (60.00)
≥ 3	12 (46.15)	8 (50.00)	4 (40.00)
Type of previous endocrine therapy combined with target therapy, n (%)
Both CDK/4/6 inhibitor and mTOR inhibitor	3 (11.54)	3 3 (18.75)	0
Only CDK4/6 inhibitor	2 (7.69)	2 (12.50)	0
Only mTOR inhibitor	2 (7.69)	2 (12.50)	0
Previous chemotherapy after metastasis, n (%)
Taxanes	26 (100)	16 (100)	10 (100)
Fluorouracil†	22 (84.62)	12 (75.00)	10 (100)
Platinum	10 (38.46)	3 (18.75)	7 (70.00)
Others‡	17 (65.38)	10 (62.50)	7 (70.00)

ECOG, Eastern Cooperative Oncology Group.†Including capecitabine and S-1. ‡Other drugs, including gemcitabine, vinorelbine, and etoposide.